Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Daniel F. Hassler is active.

Publication


Featured researches published by Daniel F. Hassler.


Molecular Cancer Therapeutics | 2007

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1

Timothy J. Lansing; Randy T. McConnell; Derek R. Duckett; Glenn M. Spehar; Victoria B. Knick; Daniel F. Hassler; Nobuhiro Noro; Masaaki Furuta; Kyle Allen Emmitte; Tona M. Gilmer; Robert A. Mook; Mui Cheung

Polo-like kinase 1 (PLK1) plays key roles in the regulation of mitotic progression, including mitotic entry, spindle formation, chromosome segregation, and cytokinesis. PLK1 expression and activity are strongly linked to proliferating cells. Many studies have shown that PLK1 expression is elevated in a variety of tumors, and high expression often correlates with poor prognosis. Using a variety of methods, including small-molecule inhibition of PLK1 function and/or activity, apoptosis in cancer cell lines, cell cycle arrest in normal cell lines, and antitumor activity in vivo have been observed. In the present study, we have examined the in vitro biological activity of a novel and selective thiophene benzimidazole ATP-competitive inhibitor of PLK1 and PLK3 (5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-{[2-(trifluoromethyl)-benzyl]oxy}thiophene-2-carboxamide, called compound 1). Compound 1 has low nanomolar activity against the PLK1 and PLK3 enzymes and potently inhibits the proliferation of a wide variety of tumor cell lines. In the lung adenocarcinoma cell line NCI-H460, compound 1 induces a transient G2-M arrest, mitotic spindle defects, and a multinucleate phenotype resulting in apoptosis, whereas normal human diploid fibroblasts arrest in G2-M and show little apoptosis. We also describe a cellular mechanistic assay that was developed to identify potent intracellular inhibitors of PLK1. In addition to its potential as a therapeutic agent for treating cancer, compound 1 is also a useful tool molecule for further investigation of the biological functions of PLK1 and PLK3. [Mol Cancer Ther 2007;6(2):450–9]


Bioorganic & Medicinal Chemistry Letters | 2009

Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.

Kyle Allen Emmitte; George M. Adjebang; C. Webb Andrews; Jennifer G. Badiang Alberti; Ramesh Bambal; Stanley D. Chamberlain; Ronda G. Davis-Ward; Hamilton D. Dickson; Daniel F. Hassler; Keith R. Hornberger; Jeffrey R. Jackson; Kevin Wayne Kuntz; Timothy J. Lansing; Robert A. Mook; Kristen E. Nailor; Mark Andrew Pobanz; Stephon C. Smith; Chiu-Mei Sung; Mui Cheung

A series of thiophene PLK1 inhibitors was optimized for increased solubility and reduced protein binding through the appendage of basic amine functionality. Interesting selectivity between PLK1 and PLK3 was also obtained through these modifications.


Bioorganic & Medicinal Chemistry Letters | 2009

Discovery of thiophene inhibitors of polo-like kinase.

Kyle Allen Emmitte; C. Webb Andrews; Jennifer Gabriel Badiang; Ronda G. Davis-Ward; Hamilton D. Dickson; David H. Drewry; Holly Kathleen Emerson; Andrea H. Epperly; Daniel F. Hassler; Victoria B. Knick; Kevin Wayne Kuntz; Timothy J. Lansing; James A. Linn; Robert A. Mook; Kristen E. Nailor; James Michael Salovich; Glenn M. Spehar; Mui Cheung

The discovery and development of a series of thiophenes as potent and selective inhibitors of PLK is described. Identification and characterization of 2, a useful in vitro PLK inhibitor tool compound, is also presented.


Bioorganic & Medicinal Chemistry Letters | 2008

Imidazo[5,1-f][1,2,4]triazin-2-amines as novel inhibitors of polo-like kinase 1

Mui Cheung; Kevin Wayne Kuntz; Mark Andrew Pobanz; James Michael Salovich; Brian John Wilson; C.W. Andrews; Lisa M. Shewchuk; Andrea H. Epperly; Daniel F. Hassler; M.A Leesnitzer; Jeffery L. Smith; Gary K. Smith; Timothy J. Lansing; Robert A. Mook

The synthesis and biological activities of imidazo[5,1-f][1,2,4]triazin-2-amines (imidazotriazines) as novel polo-like kinase 1 inhibitors are reported.


Methods in Enzymology | 2000

A high throughput sphingomyelinase assay.

Daniel F. Hassler; Ronald M. Laethem; Gary K. Smith

Publisher Summary Sphingomyelinases (SMases) are phophodiesterases that catalyze hydrolysis of the phosphodiester linkage of sphingomyelin (SM) to yield ceramide or ceramide-l-phosphate as the lipidic product and phosphorylcholine or choline as the headgroup product. SMases have been assayed using a variety of substrates. Radiolabeled sphingomyelin, prepared via incorporation of 3 H or 14 C into the headgroup moiety, is the most common substrate. Colorimetric and fluorescent assays have been developed that utilize SM analogs containing chromophores or fluors. However, these classes of substrates differ significantly from authentic SM; these are not widely used. Assays employing radiolabeled substrate require physical separation of product from substrate. Usually this separation is accomplished with liquid-liquid phase extractions that effectively separate lipophilic substrate and hydrophilic product into organic and aqueous phases, respectively. The reaction components can also be separated chromatographically. These methods are tedious and are not suitable for large numbers of samples. An alternate method employs headgroup radiolabeled SM with separation of the unreacted substrate from the labeled product by precipitation. In this strategy, the labeled substrate is selectively precipitated while the labeled headgroup product remains soluble. The latter can then be transferred easily for quantitation by liquid scintillation counting. The advantage of this method is the ease with which multiple samples can be processed simultaneously. This chapter describes methods of exploiting this separation technique to greatly increase the efficiency and throughput of SMase assays.


Journal of Biological Chemistry | 1998

Purification and characterization of a membrane bound neutral pH optimum magnesium-dependent and phosphatidylserine-stimulated sphingomyelinase from rat brain.

Bin Liu; Daniel F. Hassler; Gary K. Smith; Kurt Weaver; Yusuf A. Hannun


Archives of Biochemistry and Biophysics | 2002

Expression, preparation, and high-throughput screening of caspase-8: discovery of redox-based and steroid diacid inhibition.

Gary K. Smith; David G. Barrett; Kevin Blackburn; Michael Cory; Walter S. Dallas; Roderick G. Davis; Daniel F. Hassler; Randy T. McConnell; Mary Moyer; Kurt Weaver


Bioorganic & Medicinal Chemistry Letters | 2007

Orally active 4 -amino -5 -diarylurea -furo [2,3 -d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2

Yasushi Miyazaki; Jun Tang; Yutaka Maeda; Masato Nakano; Liping Wang; Robert T. Nolte; Hideyuki Sato; Masaki Sugai; Yuji Okamoto; Anne T. Truesdale; Daniel F. Hassler; Eldridge N. Nartey; Denis R. Patrick; Maureen L. Ho; Kazunori Ozawa


Cancer Research | 2007

Biochemical characterization of GSK461364: A novel, potent, and selective inhibitor of Polo-like kinase-1 (Plk1)

Symon Erskine; Lenore Madden; Daniel F. Hassler; Gary K. Smith; Robert Copeland; Richard Gontarek


Cancer Research | 2007

Identification of GSK461364, a novel small molecule polo-like kinase 1 inhibitor for the treatment of cancer

Kevin Wayne Kuntz; James Michael Salovich; Robert A. Mook; Kyle Allen Emmitte; Stanley D. Chamberlain; Tara Renae Rheault; Keith R. Hornberger; Holly Kathleen Emerson; Stephon C. Smith; Brian John Wilson; Ronda G. Davis-Ward; Kelly Horne Donaldson; George M. Adjabeng; Kristen E. Nailor; Daniel F. Hassler; Gary K. Smith; Timothy J. Lansing; Derek Duckett; Victoria B. Knick; Randy T. McConnell; Jeffrey Jackson; Mui Cheung

Collaboration


Dive into the Daniel F. Hassler's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge